<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04502095</url>
  </required_header>
  <id_info>
    <org_study_id>I 573720</org_study_id>
    <secondary_id>NCI-2020-04928</secondary_id>
    <secondary_id>I 573720</secondary_id>
    <nct_id>NCT04502095</nct_id>
  </id_info>
  <brief_title>Prophylactic Antibiotics for Urinary Tract Infections After Robot-Assisted Radical Cystectomy</brief_title>
  <official_title>Does Prophylactic Antibiotic Decrease the Rate of Urinary Tract Infection After Robot Assisted Radical Cystectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial investigates whether a one-month course of preventative (prophylactic) antibiotics&#xD;
      helps to reduce urinary tract infections after robot-assisted surgery to remove all of the&#xD;
      bladder as well as nearby tissues and organs (radical cystectomy). Urinary tract infections&#xD;
      are a common occurrence after robot-assisted radical cystectomy. Antibiotics such as&#xD;
      trimethoprim-sulfamethoxazole or nitrofurantoin may prevent or control infections in patients&#xD;
      with urinary tract infection and may help improve their response to radical cystectomy.&#xD;
      Information gained from this study may help researchers to predict patient complications and&#xD;
      identify better ways to manage these complications.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To determine if the utilization of a prophylactic antibiotic during the postoperative&#xD;
      period will decrease the rate of urinary tract infection (UTI) post robot-assisted radical&#xD;
      cystectomy.&#xD;
&#xD;
      SECONDARY OBJECTIVE:&#xD;
&#xD;
      I. To identify pre- and post-operative factors that may be associated with the development of&#xD;
      a 90-day UTI following radical cystectomy.&#xD;
&#xD;
      OUTLINE: Patients are randomized to 1 of 2 groups.&#xD;
&#xD;
      GROUP I (ANTIBIOTIC): Patients receive ertapenem orally (PO), levofloxacin PO, or clindamycin&#xD;
      PO induction therapy per standard of care. At the time of full diet, patients receive&#xD;
      trimethoprim-sulfamethoxazole PO daily or nitrofurantoin PO daily on days 1-30. Patients&#xD;
      complete a drug diary for each day they receive the antibiotic.&#xD;
&#xD;
      GROUP II (CONTROL): Patients receive ertapenem PO, levofloxacin PO, or clindamycin PO&#xD;
      induction therapy per standard of care.&#xD;
&#xD;
      After surgery, patients are followed up to 120 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 4, 2020</start_date>
  <completion_date type="Anticipated">August 15, 2025</completion_date>
  <primary_completion_date type="Anticipated">August 15, 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>90-day urinary tract infection (UTI) status</measure>
    <time_frame>At 90 days after surgery</time_frame>
    <description>Will be treated as dichotomous data and will be summarized by group using frequencies and relative frequencies.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Identify pre-operative factors associated with the development of UTI</measure>
    <time_frame>Up to 120 days after surgery</time_frame>
    <description>stratified logistic regression models (stratified by antibiotic use)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of Clostridium difficile (C Diff)</measure>
    <time_frame>up to 120 days after surgery</time_frame>
    <description>Will be evaluated in patients who received prophylactic antibiotics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infections occurring during antibiotic use</measure>
    <time_frame>Up to 120 days after surgery</time_frame>
    <description>To identify which antibiotic is better suited as a prophylactic, comparisons will be made using two-sided Mann-Whitney U and Fisher's exact tests for continuous and categorical variables, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identify post operative factors associated with the development of UTI</measure>
    <time_frame>Up to 120 days after surgery</time_frame>
    <description>stratified logistic regression models (stratified by antibiotic use)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Bladder Carcinoma</condition>
  <condition>Refractory Bladder Carcinoma</condition>
  <condition>Urinary Tract Infection</condition>
  <arm_group>
    <arm_group_label>Group I (trimethoprim-sulfamethoxazole, nitrofurantoin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive ertapenem PO, levofloxacin PO, or clindamycin PO induction therapy per standard of care. At the time of full diet, patients receive trimethoprim-sulfamethoxazole PO daily or nitrofurantoin PO daily on days 1-30. Patients complete a drug diary for each day they receive the antibiotic.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II (standard of care)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive ertapenem PO, levofloxacin PO, or clindamycin PO induction therapy per standard of care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clindamycin</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Group I (trimethoprim-sulfamethoxazole, nitrofurantoin)</arm_group_label>
    <arm_group_label>Group II (standard of care)</arm_group_label>
    <other_name>Cleocin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Diary</intervention_name>
    <description>Complete drug diary</description>
    <arm_group_label>Group I (trimethoprim-sulfamethoxazole, nitrofurantoin)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ertapenem</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Group I (trimethoprim-sulfamethoxazole, nitrofurantoin)</arm_group_label>
    <arm_group_label>Group II (standard of care)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levofloxacin</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Group I (trimethoprim-sulfamethoxazole, nitrofurantoin)</arm_group_label>
    <arm_group_label>Group II (standard of care)</arm_group_label>
    <other_name>(S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic Acid Hydrate (2:1)</other_name>
    <other_name>Levaquin</other_name>
    <other_name>Levofloxacin Hydrate</other_name>
    <other_name>Quixin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitrofurantoin</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Group I (trimethoprim-sulfamethoxazole, nitrofurantoin)</arm_group_label>
    <other_name>Macrobid</other_name>
    <other_name>Macrodantin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trimethoprim-Sulfamethoxazole</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Group I (trimethoprim-sulfamethoxazole, nitrofurantoin)</arm_group_label>
    <other_name>Bactrim</other_name>
    <other_name>Bactrim DS</other_name>
    <other_name>Bactrimel</other_name>
    <other_name>Centran</other_name>
    <other_name>Centrin</other_name>
    <other_name>Co-Trimoxazole</other_name>
    <other_name>Cotrim</other_name>
    <other_name>Cotrimoxazole</other_name>
    <other_name>Eslectin</other_name>
    <other_name>Insozalin</other_name>
    <other_name>Septra</other_name>
    <other_name>SMZ-TMP</other_name>
    <other_name>Sulfamethoprim</other_name>
    <other_name>Sulfatrim</other_name>
    <other_name>Sulmeprim</other_name>
    <other_name>TMP-SMX</other_name>
    <other_name>Trimedin</other_name>
    <other_name>Trimezole</other_name>
    <other_name>Uroplus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Any patient that electively chooses to have a cystectomy is eligible to participate in&#xD;
             the study. Indications for a person who may undergo a cystectomy include having a&#xD;
             diagnosis of muscle-invasive bladder cancer (MIBC) or refractory non-muscle invasive&#xD;
             bladder cancer (NMIBC)&#xD;
&#xD;
          -  Any patient that will electively choose to have a robot-assisted radical cystectomy&#xD;
             and is able to provide consent&#xD;
&#xD;
          -  Participant or legal representative must understand the investigational nature of this&#xD;
             study and sign an Independent Ethics Committee/Institutional Review Board approved&#xD;
             written informed consent form prior to receiving any study related procedure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a history of myasthenia gravis&#xD;
&#xD;
          -  Patients with a history of QT prolongation or taking other drugs that prolong&#xD;
             corrected QTc (QTc) should be excluded&#xD;
&#xD;
          -  Patients with renal dysfunction, creatinine clearance (mL/min) &lt; 30&#xD;
&#xD;
          -  Pregnant or nursing female participants&#xD;
&#xD;
          -  Females who receive a fertile sex sparing robot-assisted radical cystectomy (RARC)&#xD;
&#xD;
          -  Unwilling or unable to follow protocol requirements&#xD;
&#xD;
          -  Patients who receive a prophylactic antibiotic or antibiotic for any other reason&#xD;
             prior to discharge&#xD;
&#xD;
          -  Any condition which in the investigator's opinion deems the participant an unsuitable&#xD;
             candidate to receive study drug&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Khurshid A Guru</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Khurshid A. Guru</last_name>
      <phone>716-845-4107</phone>
      <email>Khurshid.Guru@roswellpark.org</email>
    </contact>
    <investigator>
      <last_name>Khurshid A. Guru</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>July 24, 2020</study_first_submitted>
  <study_first_submitted_qc>August 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2020</study_first_posted>
  <last_update_submitted>June 22, 2021</last_update_submitted>
  <last_update_submitted_qc>June 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
    <mesh_term>Trimethoprim</mesh_term>
    <mesh_term>Trimethoprim, Sulfamethoxazole Drug Combination</mesh_term>
    <mesh_term>Nitrofurantoin</mesh_term>
    <mesh_term>Clindamycin</mesh_term>
    <mesh_term>Ertapenem</mesh_term>
    <mesh_term>Sulfamethoxazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

